A Phase IIIb, Open-Label, Multicenter, Observational, Non-Comparative Study Assessing Longterm Efficacy And Safety Of Somatropin In Adult Patients With Growth Hormone Deficiency (GHD)

Trial Profile

A Phase IIIb, Open-Label, Multicenter, Observational, Non-Comparative Study Assessing Longterm Efficacy And Safety Of Somatropin In Adult Patients With Growth Hormone Deficiency (GHD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 New trial record
    • 04 Apr 2017 Results of interim analysis (up to 24 months treatment) assessing effect of somatropin on body composition and bone mineral density, presented at The 99th Annual Meeting of the Endocrine Society.
    • 04 Apr 2017 Interim results of data up to 24 months of treatment, presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top